Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MapLight Therapeutics, Inc.MPLT · Entity 5316 | Chief Financial Officer | May 04, 2026 | May 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MapLight Therapeutics, Inc.
Report date May 04, 2026 · Filed May 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Voting Common StockSEC Table I · non-derivative | Direct | 356,256 |
Ending reported balance
After 2026-05-06 transaction · row 8
8 source rows · reconciled sequenceRow 1 · 2026-05-04 · Sale · Disposed 4,803 · Balance 387,824 F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.84 to $27.835 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 2 · 2026-05-04 · Sale · Disposed 8,989 · Balance 378,835 F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.845 to $28.74 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 3 · 2026-05-04 · Sale · Disposed 325 · Balance 378,510 F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.9669 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 4 · 2026-05-04 · Sale · Disposed 787 · Balance 377,723 F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.55 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 5 · 2026-05-05 · Sale · Disposed 9,935 · Balance 367,788 F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.755 to $28.75 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 6 · 2026-05-05 · Sale · Disposed 968 · Balance 366,820 F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.79 to $29.26 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 7 · 2026-05-06 · Sale · Disposed 8,496 · Balance 358,324 F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.675 to $28.6587 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 8 · 2026-05-06 · Sale · Disposed 2,068 · Balance 356,256 F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.73 to $29.35 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.84 to $27.835 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.845 to $28.74 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.9669 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.55 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.755 to $28.75 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.79 to $29.26 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.675 to $28.6587 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.73 to $29.35 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 06, 2026 Filed May 7, 2026 00:15 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 2,068 | $29.07 | $60,116.76 |
DisclosureSEC source: 0002021256-26-000008 · form4-05062026_080509.xml · nonDerivative · entry 8 Setia Vishwas · CIK 0002021256 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 356,256 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.73 to $29.35 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 06, 2026 Filed May 7, 2026 00:15 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 8,496 | $28.04 | $238,227.84 |
DisclosureSEC source: 0002021256-26-000008 · form4-05062026_080509.xml · nonDerivative · entry 7 Setia Vishwas · CIK 0002021256 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 358,324 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.675 to $28.6587 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 05, 2026 Filed May 7, 2026 00:15 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 968 | $29.00 | $28,072.00 |
DisclosureSEC source: 0002021256-26-000008 · form4-05062026_080509.xml · nonDerivative · entry 6 Setia Vishwas · CIK 0002021256 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 366,820 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.79 to $29.26 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 05, 2026 Filed May 7, 2026 00:15 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 9,935 | $28.12 | $279,372.20 |
DisclosureSEC source: 0002021256-26-000008 · form4-05062026_080509.xml · nonDerivative · entry 5 Setia Vishwas · CIK 0002021256 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 367,788 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.755 to $28.75 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 04, 2026 Filed May 7, 2026 00:15 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 787 | $30.12 | $23,704.44 |
DisclosureSEC source: 0002021256-26-000008 · form4-05062026_080509.xml · nonDerivative · entry 4 Setia Vishwas · CIK 0002021256 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 377,723 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.55 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 04, 2026 Filed May 7, 2026 00:15 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 325 | $29.56 | $9,607.00 |
DisclosureSEC source: 0002021256-26-000008 · form4-05062026_080509.xml · nonDerivative · entry 3 Setia Vishwas · CIK 0002021256 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 378,510 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.9669 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 04, 2026 Filed May 7, 2026 00:15 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 8,989 | $28.28 | $254,208.92 |
DisclosureSEC source: 0002021256-26-000008 · form4-05062026_080509.xml · nonDerivative · entry 2 Setia Vishwas · CIK 0002021256 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 378,835 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.845 to $28.74 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 04, 2026 Filed May 7, 2026 00:15 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 4,803 | $27.36 | $131,410.08 |
DisclosureSEC source: 0002021256-26-000008 · form4-05062026_080509.xml · nonDerivative · entry 1 Setia Vishwas · CIK 0002021256 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 387,824 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.84 to $27.835 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 16, 2026 Filed Apr 17, 2026 20:05 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 87 | $27.49 | $2,391.63 |
DisclosureSEC source: 0002021256-26-000006 · form4-04172026_040410.xml · nonDerivative · entry 3 Setia Vishwas · CIK 0002021256 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 392,627 F1 · shares: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.22 to $27.9898 inclusive. Read SEC document |
| April 16, 2026 Filed Apr 17, 2026 20:05 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 29 | $27.01 | $783.29 |
DisclosureSEC source: 0002021256-26-000006 · form4-04172026_040410.xml · nonDerivative · entry 2 Setia Vishwas · CIK 0002021256 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 392,714 F1 · shares: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.2201 to $27.2197 inclusive. Read SEC document |
| April 15, 2026 Filed Apr 17, 2026 20:05 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | SaleVoting Common Stock | 2,806 | $26.87 | $75,397.22 |
DisclosureSEC source: 0002021256-26-000006 · form4-04172026_040410.xml · nonDerivative · entry 1 Setia Vishwas · CIK 0002021256 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 392,743 F1 · shares: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.33 to $27.29 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4). Read SEC document |
| February 05, 2026 Filed Feb 9, 2026 22:50 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | GrantEmployee Stock Option (right to buy) · Derivative | 31,395 | $0.00 Strike: $15.70 | $0.00 |
DisclosureSEC source: 0002021256-26-000004 · form4-02092026_050210.xml · derivative · entry 2 Setia Vishwas · CIK 0002021256 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,395 Underlying: Voting Common Stock · 31,395 shares Expires 2036-02-04 F3 · derivative.exercise_date: 1/4th of the total shares underlying the option shall vest on February 5, 2027, and 1/48th of the total shares shall vest each month thereafter on the same day of the month, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| February 05, 2026 Filed Feb 9, 2026 22:50 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | GrantVoting Common Stock | 7,730 | $0.00 | $0.00 |
DisclosureSEC source: 0002021256-26-000004 · form4-02092026_050210.xml · nonDerivative · entry 1 Setia Vishwas · CIK 0002021256 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 395,549 F1 · shares: Represents a restricted stock unit ("RSU") award. 1/4th of the RSUs shall vest on January 1, 2027, and 1/16th of the RSUs shall vest on each subsequent April 1, July 1, October 1 and January 1 thereafter, subject to the Reporting Person's continued service through each vesting date. F2 · price: Each RSU represents a contingent right to receive one share of voting common stock of the Issuer. Read SEC document |
| January 27, 2026 Filed Jan 29, 2026 21:30 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | Tax withholdingVoting Common Stock | 33,382 | $17.98 | $600,208.36 |
DisclosureSEC source: 0002021256-26-000002 · form4-01292026_040112.xml · nonDerivative · entry 1 Setia Vishwas · CIK 0002021256 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 387,819 F1 · shares: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations in connection with the settlement of a restricted stock unit award. The securities of the Issuer retained by the Reporting Person remain subject to the terms a lock-up agreement entered into with the underwriters for the Issuer's initial public offering, pursuant to which the Reporting Person agreed, subject to certain exceptions, not to directly or indirectly sell or otherwise transfer securities of the Issuer for a period of 180 days following the date of the final prospectus relating to the initial public offering, which was October 26, 2025. Read SEC document |
| October 27, 2025 Filed Oct 28, 2025 20:15 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | GrantEmployee Stock Option (right to buy) · Derivative | 176,031 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0002021256-25-000006 · form4-10282025_041009.xml · derivative · entry 2 Setia Vishwas · CIK 0002021256 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 176,031 Underlying: Voting Common Stock · 176,031 shares Expires 2035-10-26 F3 · derivative.exercise_date: 1/4th of the total shares underlying the option shall vest on October 1, 2026, and 1/48th of the total shares shall vest each month thereafter on the same day of the month, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| October 27, 2025 Filed Oct 28, 2025 20:15 UTC | MapLight Therapeutics, Inc. MPLT · Entity 5316 | GrantVoting Common Stock | 43,367 | $0.00 | $0.00 |
DisclosureSEC source: 0002021256-25-000006 · form4-10282025_041009.xml · nonDerivative · entry 1 Setia Vishwas · CIK 0002021256 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,367 F1 · shares: Represents a restricted stock unit ("RSU") award. 1/4th of the RSUs shall vest on October 1, 2026, and 1/16th of the RSUs shall vest on each subsequent January 1, April 1, July 1 and October 1 thereafter, subject to the Reporting Person's continued service through each vesting date. F2 · price: Each RSU represents a contingent right to receive one share of voting common stock of the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.